Salhab M, Reed M J, Al Sarakbi W, Jiang W G, Mokbel K
St George's Hospital, Blackshaw Road, London, Tooting, UK.
Breast Cancer Res Treat. 2006 Sep;99(2):155-62. doi: 10.1007/s10549-006-9198-8. Epub 2006 Mar 16.
There is substantial evidence that breast cancer tissue contains all the enzymes responsible for the local biosynthesis of estrogens from circulating precursors. The cytochrome P-450 aromatase enzyme complex is responsible for the conversion of C19 androgens to estrogens and 17-beta-hydroxysteroid dehydrogenase (17-I(2)-HSD) type 1 catalyses the inter-conversion of estrone to the biologically more potent estradiol. The gene encoding for the cytochrome P-450 aromatase is known as CYP19 (15q21.2). It is well established that increased exposure to local estrogens is an important risk factor in the genesis and growth of breast cancer. The aim of this study is to investigate the relationship between CYP19 and 17-beta-HSD type 1A mRNA expression and clinico-pathological parameters of human breast cancer.
One hundred and twenty seven tumor tissues and 33 normal tissues were analyzed. The levels of transcription of CYP19 and 17-beta-HSD type 1 were determined using real-time quantitative PCR. The mRNA expression was normalized against CK19. Levels of expression were analyzed against tumorâ's stage, grade, nodal status, local relapse, distant metastasis and survival over a 120A months follow up period. In addition, the levels were analyzed against estrogen receptor (ER) and HER1-4 status.
Overall, high tumor levels of mRNA expression of CYP19 and 17-beta-HSD type 1 correlated with poor survival (p=0.0105 and p=0.0182, respectively). Increased levels of CYP19 mRNA expression positively correlated with disease progression as levels were significantly higher in samples of patients who had distant metastasis and local recurrence and/or died of breast related causes when compared to those who were disease free for >10 years (p=0.0015). We also observed higher levels of CYP19 mRNA in tumor samples compared to normal breast tissue. However, this reached statistical significance only when comparing grade 1 tumors with normal tissue (p=0.01). There was no correlation between CYP19á mRNA expression and tumor stage, lymph node status and tumor grade. There was however a trend for a positive correlation between CYP19 and ER mRNA expressions (p=0.06). No significant difference in 17-beta-HSD type 1 expression between normal and cancerous tissues was observed. In tumor samples, we observed an increase in levels correlating with tumor's grade. This correlation was statistically significant when we compared grade 1 with grade 2 and grade 1 with grade 3 (p=0.0031 and 0.0251, respectively).
Our study shows that higher levels of the enzymes responsible for the local biosynthesis of estrogens especially aromatase are associated with a poor clinical outcome in patients with breast cancer.
有大量证据表明,乳腺癌组织含有所有负责从循环前体物质进行雌激素局部生物合成的酶。细胞色素P-450芳香化酶复合物负责将C19雄激素转化为雌激素,而1型17-β-羟基类固醇脱氢酶(17-β-HSD)催化雌酮与生物活性更强的雌二醇之间的相互转化。编码细胞色素P-450芳香化酶的基因称为CYP19(15q21.2)。众所周知,局部雌激素暴露增加是乳腺癌发生和生长的重要危险因素。本研究的目的是探讨CYP19和1型17-β-HSD mRNA表达与人类乳腺癌临床病理参数之间的关系。
分析了127个肿瘤组织和33个正常组织。使用实时定量PCR测定CYP19和1型17-β-HSD的转录水平。mRNA表达以CK19为对照进行标准化。根据肿瘤分期、分级、淋巴结状态、局部复发、远处转移以及120个月随访期内的生存率分析表达水平。此外,还根据雌激素受体(ER)和HER1-4状态分析了这些水平。
总体而言,CYP19和1型17-β-HSD的高肿瘤mRNA表达水平与较差的生存率相关(分别为p=0.0105和p=0.0182)。CYP19 mRNA表达水平升高与疾病进展呈正相关,因为与无病超过10年的患者相比,发生远处转移和局部复发及/或死于乳腺癌相关原因的患者样本中的水平显著更高(p=0.0015)。我们还观察到肿瘤样本中的CYP19 mRNA水平高于正常乳腺组织。然而,仅在将1级肿瘤与正常组织进行比较时才达到统计学显著性(p=0.01)。CYP19α mRNA表达与肿瘤分期、淋巴结状态和肿瘤分级之间无相关性。然而,CYP19与ER mRNA表达之间存在正相关趋势(p=0.06)。未观察到正常组织与癌组织之间1型17-β-HSD表达的显著差异。在肿瘤样本中,我们观察到水平升高与肿瘤分级相关。当我们将1级与2级以及将1级与3级进行比较时,这种相关性具有统计学显著性(分别为p=0.0031和p=0.0251)。
我们的研究表明,负责雌激素局部生物合成的酶,尤其是芳香化酶的较高水平与乳腺癌患者不良的临床结局相关。